Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials-Reference-Cited by-同舟云学术

Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials

Published:2022-08-10 Issue:2 Volume:19 Page:696-707
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Langbaum Jessica B.¹,Zissimopoulos Julie²,Au Rhoda³,Bose Niranjan⁴,Edgar Chris J.⁵,Ehrenberg Evan⁶,Fillit Howard⁷,Hill Carl V.⁸,Hughes Lynne⁹,Irizarry Michael¹⁰,Kremen Sarah¹¹,Lakdawalla Darius¹²,Lynn Nancy¹³,Malzbender Kristina⁴,Maruyama Tetsuyuki¹⁴,Massett Holly A.¹⁵,Patel Deep¹⁶,Peneva Desi¹²,Reiman Eric M.¹,Romero Klaus¹⁷,Routledge Carol¹⁸,Weiner Michael W.¹⁹,Weninger Stacie²⁰,Aisen Paul S.²¹

Affiliation:

1. Banner Alzheimer's Institute Phoenix Arizona USA

2. Sol Price School of Public Policy and Leonard D. Schaeffer Center for Health Policy and Economics University of Southern California Los Angeles California USA

3. Departments of Anatomy & Neurobiology Neurology and Epidemiology Boston University Schools of Medicine and Public Health Boston Massachusetts USA

4. Gates Ventures Kirkland Washington USA

5. Cogstate Ltd Reading UK

6. Clara Health San Francisco California USA

7. Alzheimer's Drug Discovery Foundation New York New York USA

8. Alzheimer's Association Chicago Illinois USA

9. Lynne Hughes Consulting Berkshire UK

10. Eisai Woodcliff Lake New Jersey USA

11. The Jona Goldrich Center for Alzheimer's and Memory Disorders Department of Neurology Cedars‐Sinai Medical Center Los Angeles California USA

12. Leonard D. Schaeffer Center for Health Policy and Economics University of Southern California Los Angeles California USA

13. BrightFocus Foundation Clarksburg Maryland USA

14. Alzheimer's Disease Data Initiative Kirkland Washington USA

15. National Institute on Aging Bethesda Maryland USA

16. IQVIA New York New York USA

17. Critical Path Institute Tucson Arizona USA

18. Small Pharma Ltd London UK

19. Departments of Radiology and Biomedical Imaging Medicine, Psychiatry, and Neurology University of California San Francisco San Francisco California USA

20. FBRI Cambridge Massachusetts USA

21. Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12737

Reference68 articles.

1. 2021 Alzheimer's disease facts and figures

2. The Value of Delaying Alzheimer’s Disease Onset

3. Impact of interventions to reduce Alzheimer's disease pathology on the prevalence of dementia in the oldest‐old

4. Accelerating Alzheimer's disease drug innovations from the research pipeline to patients

5. Alzheimer's disease drug development pipeline: 2021

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-person and remote recruitment of people with dementia into a primary care-based cluster randomised controlled trial: lessons from the Dementia PersonAlised Care Team (D-PACT) feasibility study;2024-02-01

2. Rescreening on RBANS Delayed Memory Index? Forget About It!;Alzheimer Disease & Associated Disorders;2024-01-25

3. Participant completion of longitudinal assessments in an online cognitive aging registry: The role of medical conditions;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-01

4. TWINGEN – protocol for an observational clinical biobank recall and biomarker study to identify individuals with high risk of Alzheimer’s disease;2023-11-04

5. Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches;Neuroscience Letters;2023-11